Claims for Patent: 6,572,852

✉ Email this page to a colleague

Summary for Patent: 6,572,852

Title:	Method for suppressing inflammatory responses by administering TNFR
Abstract:	Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
Inventor(s):	Smith; Craig A. (Seattle, WA), Goodwin; Raymond G. (Seattle, WA), Beckmann; M. Patricia (Poulsbo, WA)
Assignee:	Immunex Corporation (Seattle, WA)
Application Number:	09/758,124
Patent Claims:	1. A method of suppressing a TNF-dependent inflammatory response in a mammal comprising administering an effective amount of recombinant tumor necrosis factor receptor (TNFR) to a mammal afflicted with said inflammatory response, wherein said recombinant TNFR comprises amino acids 1-163 of SEQ ID NO:2. 2. The method of claim 1, wherein said recombinant TNFR consists essentially of amino acids 1-163 of SEQ ID NO:2. 3. The method of claim 2, wherein said recombinant TNFR comprises amino acids 1-185 of SEQ ID NO:2. 4. The method of claim 3, wherein said recombinant TNFR comprises amino acids 1-235 of SEQ ID NO:2. 5. A method of suppressing a TNF-dependent inflammatory response in a mammal comprising administering an effective amount of tumor necrosis factor receptor (TNFR) to a mammal afflicted with said inflammatory response, wherein said TNFR comprises amino acids 1-163 of SEQ ID NO:2. 6. The method of claim 5, wherein said TNFR consists essentially of amino acids 1-163 of SEQ ID NO:2. 7. The method of claim 6, wherein said TNFR comprises amino acids 1-185 of SEQ ID NO:2. 8. The method of claim 7, wherein said TNFR comprises amino acids 1-235 of SEQ ID NO:2.

Details for Patent 6,572,852

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	⤷ Subscribe	2009-09-05
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	⤷ Subscribe	2009-09-05
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	⤷ Subscribe	2009-09-05
Immunex Corporation	ENBREL	etanercept	Injection	103795	February 01, 2007	⤷ Subscribe	2009-09-05
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 6,572,852

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
South Africa	907072	⤷ Subscribe
World Intellectual Property Organization (WIPO)	9406476	⤷ Subscribe
World Intellectual Property Organization (WIPO)	9319777	⤷ Subscribe
World Intellectual Property Organization (WIPO)	9103553	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.